Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg
{"title":"The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.","authors":"Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg","doi":"10.1080/14737175.2024.2355981","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.</p><p><strong>Areas covered: </strong>In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials. The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments.</p><p><strong>Expert opinion: </strong>While the patch is bio-equivalent, it is rather large and may not be affordable for some patients. In addition, there is no high dose (e.g. 23 mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2024.2355981","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.
Areas covered: In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials. The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments.
Expert opinion: While the patch is bio-equivalent, it is rather large and may not be affordable for some patients. In addition, there is no high dose (e.g. 23 mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.
简介:胆碱酯酶抑制剂和美金刚是AD(阿尔茨海默病)对症治疗的主要药物;然而,这些药物通常都是口服给药,这对AD患者及其护理人员来说可能很困难:在这篇药物简介和叙述性综述中,作者追溯了经 FDA 批准的新透皮多奈哌齐的发展历程。作者讨论了显示其与口服制剂生物等效性的研究,包括两项双盲安慰剂对照非劣效性试验。作者还将该贴剂与市场上唯一一种透皮胆碱酯酶抑制剂利伐斯的明进行了比较,并强调了这两种治疗方法之间潜在的优缺点:专家意见:虽然这种贴片具有生物等效性,但其体积较大,一些患者可能负担不起。此外,也没有高剂量(如 23 毫克)的同等药物。尽管如此,鉴于其有效性和潜在的便利性,透皮多奈哌齐对注意力缺失症患者及其护理人员还是很有用的。
期刊介绍:
Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points